Skip to content
Subscriber Only

Gilead’s Hepatitis C Pill Works Better, FDA Report Says

Gilead Sciences Inc.’s experimental hepatitis C drug that lessens side effects and reduces length of treatment time is safe and effective against the disease, U.S. regulators said.

The medicine, sofosbuvir, has “a favorable benefit-risk assessment,” Food and Drug Administration staff said today in a review ahead of an Oct. 25 meeting of advisers to discuss the therapy. The FDA also will host an advisory panel tomorrow for Johnson & Johnson and Medivir AB’s hepatitis C drug simeprevir.